Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives

References

• Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009.
   PubMed Web of Science ®Google Scholar
• Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the united states over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–4544.
   PubMed Web of Science ®Google Scholar
• Colby TV, Wistuba II, Gazdar A. Precursors to pulmonary neoplasia. Adv Anat Pathol. 1998;5(4):205–215.
   PubMedGoogle Scholar
• Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007;25(5):561–570.
   PubMed Web of Science ®Google Scholar
• Borri A, Leo F, Veronesi G, et al. Extended pneumonectomy for non–small cell lung cancer: morbidity, mortality, and long-term results. J Thorac Cardiovasc Surg. 2007;134(5):1266–1272.
   PubMed Web of Science ®Google Scholar
• Spaggiari L, Galetta D, Veronesi G, et al. Superior vena cava replacement for lung cancer using a heterologous (bovine) prosthesis: preliminary results. J Thorac Cardiovasc Surg. 2006;131(2):490–491.
   PubMed Web of Science ®Google Scholar
• Petrella F, Chieco P, Solli P, et al. Which factors affect pulmonary function after lung metastasectomy? Eur J Cardio-Thoracic Surg. 2009;35(5):792–796.
   PubMed Web of Science ®Google Scholar
• Petrella F, Coccè V, Masia C, et al. Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells. Biomed Pharmacother. 2017;87(Supplement C):755–758.
   PubMedGoogle Scholar
• Bini A, Grazia M, Petrella F, et al. Multiple chondromatous hamartomas of the lung. Interact Cardiovasc Thorac Surg. 2002;1(2):78–80.
   PubMedGoogle Scholar
• Britton M. The epidemiology of mesothelioma. Semin Oncol. 2002;29(1):18–25.
   PubMed Web of Science ®Google Scholar
• Novello S, Pinto C, Torri V, et al. The third italian consensus conference for malignant pleural mesothelioma: state of the art and recommendations. Crit Rev Oncol Hematol. 2016;104:9–20.
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Temin S, Aliff T, et al. Focused update of 2009 american society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer. J Clin Oncol. 2011;29(28):3825–3831.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non–small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–3551.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006;355(24):2542–2550.
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non–small-cell lung cancer. J Clin Oncol. 2013;31(23):2895–2902.
   PubMed Web of Science ®Google Scholar
• Kang F, Ai Y, Zhang Y, et al. Design and synthesis of new hybrids from 2-cyano-3,12-dioxooleana- 9-dien-28-oic acid and O2-(2,4-dinitrophenyl) diazeniumdiolate for intervention of drug-resistant lung cancer. Eur J Med Chem. 2018;149:269–280.
   PubMed Web of Science ®Google Scholar
• Li X, Guise CP, Taghipouran R, et al. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. Eur J Med Chem. 2017;135:531–543.
   PubMed Web of Science ®Google Scholar
• Chamni S, Sirimangkalakitti N, Chanvorachote P, et al. Chemistry of renieramycins. 17. A new generation of renieramycins: hydroquinone 5-O-monoester analogues of renieramycin M as potential cytotoxic agents against non-small-cell lung cancer cells. J Nat Prod. 2017;80(5):1541–1547.
   PubMed Web of Science ®Google Scholar
• Yin J-Y, Li X, Zhou -H-H, et al. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine. Pharmacogenomics. 2016;17(12):1365–1378.
   PubMed Web of Science ®Google Scholar
• Rahman F-U, Bhatti MZ, Ali A, et al. Homo- and heteroleptic Pt(II) complexes of ONN donor hydrazone and 4-picoline: A synthetic, structural and detailed mechanistic anticancer investigation. Eur J Med Chem. 2018;143:1039–1052.
   PubMed Web of Science ®Google Scholar
• Sieste S, Lifincev I, Stein N, et al. Synthesis, characterisation and in vitro cytotoxicity of mixed ligand Pt(ii) oxadiazoline complexes with hexamethylenetetramine and 7-nitro-1,3,5-triazaadamantane. Dalton Trans. 2017;46(36):12226–12238.
   PubMed Web of Science ®Google Scholar
• Huang X, Huang R, Gou S, et al. Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance. Bioorg Med Chem. 2017;25(17):4686–4700.
   PubMed Web of Science ®Google Scholar
• Bauer E, Domingo X, Balcells C, et al. Synthesis, characterization and biological activity of new cyclometallated platinum(iv) iodido complexes. Dalton Trans. 2017;46(43):14973–14987.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non–small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23(11):2556–2568.
   PubMed Web of Science ®Google Scholar
• Mok T, Yang -J-J, Lam K-C. Treating patients with EGFR-sensitizing mutations: first line or second line—is there a difference? J Clin Oncol. 2013;31(8):1081–1088.
   PubMed Web of Science ®Google Scholar
• Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19:1389.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non–small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971.
   PubMed Web of Science ®Google Scholar
• Rybarczyk-Kasiuchnicz A, Ramlau R. Current views on molecularly targeted therapy for lung cancer – a review of literature from the last five years. Polish J Thorac Cardiovasc Surg. 2018;15(2):119–124.
   Web of Science ®Google Scholar
• Nguyen-Ngoc T, Bouchaab H, Adjei AA, et al. BRAF alterations as therapeutic targets in non–small-cell lung cancer. J Thorac Oncol. 2015;10(10):1396–1403.
   PubMed Web of Science ®Google Scholar
• Hayashi H, Nakagawa K. Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation. J Thorac Dis. 2016;8(10):E1311–E16.
   PubMed Web of Science ®Google Scholar
• Shine Raju, RJ., Sehgal, S Review of checkpoint immunotherapy for the management of non-small cell lung cancer. ImmunoTargets Ther. 2018;7:63–75.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252.
   PubMed Web of Science ®Google Scholar
• Immunologic DHR. Clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther. 2014;96(2):214–223.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644.
   PubMed Web of Science ®Google Scholar
• Facchetti G, Petrella F, Spaggiari L, et al. Malignant pleural mesothelioma: state of the art and advanced cell therapy. Eur J Med Chem. 2017;142(Supplement C):266–270.
   PubMedGoogle Scholar
• Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623–630.
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Zucali PA, De Vincenzo F, et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer. 2011;72(1):73–77.
   PubMed Web of Science ®Google Scholar
• Marcella B, Daniele C, Riccardo I, et al. Possible repurposing of pyrvinium pamoate for the treatment of mesothelioma: a pre-clinical assessment. J Cell Physiol. 2018;233(9):7391–7401.
   PubMed Web of Science ®Google Scholar
• Yoshiko K, Hisao N, Ayako T, et al. Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma. Cancer Sci. 2014;105(7):883–889.
   PubMed Web of Science ®Google Scholar
• Cincinelli R, Musso L, Artali R, et al. Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors. Eur J Med Chem. 2018;143:2005–2014.
   PubMed Web of Science ®Google Scholar
• Ang WH, Khalaila I, Allardyce CS, et al. Rational design of platinum(IV) compounds to overcome glutathione-s-transferase mediated drug resistance. J Am Chem Soc. 2005;127(5):1382–1383.
   PubMed Web of Science ®Google Scholar
• Zanellato I, Bonarrigo I, Sardi M, et al. Evaluation of platinum–ethacrynic acid conjugates in the treatment of mesothelioma. ChemMedChem. 2011;6(12):2287–2293.
   PubMed Web of Science ®Google Scholar
• Gabano E, Ravera M, Trivero F, et al. The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions. Dalton Trans. 2018;47(25):8268–8282.
   PubMed Web of Science ®Google Scholar
• Ravera M, Gabano E, Zanellato I, et al. Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(iv) complexes based on picoplatin. Dalton Trans. 2012;41(11):3313–3320.
   PubMed Web of Science ®Google Scholar
• Rimoldi I, Facchetti G, Lucchini G, et al. In vitro anticancer activity evaluation of new cationic platinum(II) complexes based on imidazole moiety. Bioorg Med Chem. 2017;25(6):1907–1913.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
   PubMed Web of Science ®Google Scholar
• Sul J, Blumenthal GM, Jiang X, et al. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist. 2016;21(5):643–650.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Roden AC, Peikert T, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014;9(7):1036–1040.
   PubMed Web of Science ®Google Scholar
• Quispel-Janssen J, van der Noort V, de Vries JF, et al. PD-1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018. pii: S1556-0864(18)30688-9. doi: 10.1016/j.jtho.2018.05.038.
   PubMedGoogle Scholar
• Petrella F, Rizzo S, Borri A, et al. Current perspectives in mesenchymal stromal cell therapies for airway tissue defects. Stem Cells Int. 2015;2015:7.
   Google Scholar
• Rizzo S, Petrella F, Zucca I, et al. In vitro labelling and detection of mesenchymal stromal cells: a comparison between magnetic resonance imaging of iron-labelled cells and magnetic resonance spectroscopy of fluorine-labelled cells. Eur Radiol Exp. 2017 June 29;1(1):6.
   Google Scholar
• Petrella F, Toffalorio F, Brizzola S, et al. Stem cell transplantation effectively occludes bronchopleural fistula in an animal model. Ann Thorac Surg. 2013;97(2):480–483.
   PubMed Web of Science ®Google Scholar
• Pessina A, Bonomi A, Coccè V, et al. mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS One. 2011;6(12):e28321.
   PubMed Web of Science ®Google Scholar
• CT SJ H, Tsai JY, Hsueh CT. Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World J Gastroenterol. 2016;22(31):7080–7090.
   PubMed Web of Science ®Google Scholar
• Rimoldi I, Coccè V, Facchetti G, et al. Uptake-release by MSCs of a cationic platinum(II) complex active in vitro on human malignant cancer cell lines. Biomed Pharmacother. 2018;108:111–118.
   PubMedGoogle Scholar
• Spaggiari L, Petrella F. Small cell lung cancer ESTS textbook of thoracic surgery. Medycyna Praktyczna. 2014;1:825–832.
   Google Scholar
• Ferrara R, Mezquita L, Besse B. Progress in the management of advanced thoracic malignancies in 2017. J Thorac Oncol. 2018;13(3):301–322.
   PubMed Web of Science ®Google Scholar
• Venuta F, Anile M, Vitolo D, et al. Thymoma and thymic carcinoma chapter ESTS textbook of thoracic surgery. Medycyna Praktyczna. 2014;2:277–294.
   Google Scholar